Gilead, GSK could be impacted by potential HHS HIV prevention cuts Posted on March 18, 2025 by wpadmin Gam1983 Cuts to domestic HIV prevention programs reportedly under consideration by HHS could negatively impact two of the largest HIV drugmakers, Gilead Sciences (NASDAQ:GILD) and GSK (NYSE:GSK), which is the majority owner of ViiV Healthcare. The potential cuts were reported by
